<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467870</url>
  </required_header>
  <id_info>
    <org_study_id>IP157-001</org_study_id>
    <nct_id>NCT00467870</nct_id>
  </id_info>
  <brief_title>Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men</brief_title>
  <acronym>TU</acronym>
  <official_title>A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of TU 750 mg and TU 1000 mg via multiple measurements of
      serum total testosterone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
    <description>Responders were participants with serum total testosterone average concentration (Cavg) between 300 and 1000 ng/dL derived from the 3rd injection intensive pharmacokinetic (IPK) interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Total Testosterone Average Concentration During the 3rd Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
    <description>Serum total testosterone Cavg derived from the 3rd injection IPK interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Total Testosterone Maximum Concentration During the 3rd Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
    <description>Serum total testosterone maximum concentration (Cmax) derived from the 3rd injection IPK interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 3rd Injection in Part C</measure>
    <time_frame>Day 70 post injection at week 14</time_frame>
    <description>Serum total testosterone concentration at the end of the dosing interval (Ctrough) derived from the 3rd injection IPK interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 4th Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
    <description>Responders were participants with serum total testosterone Cavg between 300 and 1000 ng/dL derived from the 4th injection IPK interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Total Testosterone Average Concentration During the 4th Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
    <description>Serum total testosterone Cavg derived from the 4th injection IPK interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Total Testosterone Maximum Concentration During the 4th Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
    <description>Serum total testosterone Cmax derived from the 4th injection IPK interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 4th Injection in Part C</measure>
    <time_frame>Day 70 post injection at week 24</time_frame>
    <description>Serum total testosterone Ctrough derived from the 4th injection IPK interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 2nd Injection Interval in Part C2</measure>
    <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
    <description>Success was defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax &gt;2500 ng/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Total Testosterone Average Concentration During the 2nd Injection Interval in Part C2</measure>
    <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
    <description>Serum total testosterone Cavg derived from the 2nd injection IPK interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Total Testosterone Maximum Concentration During the 2nd Injection Interval in Part C2</measure>
    <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
    <description>Serum total testosterone Cmax derived from the 2nd injection IPK interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Total Testosterone at the End of the Dosing Interval Following the 2nd Injection in Part C2</measure>
    <time_frame>Day 70 post injection at week 4</time_frame>
    <description>Serum total testosterone Ctrough derived from the 2nd injection IPK interval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Total Testosterone Maximum Concentration in Part A</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, 70, and 84 post injection at week 1, week 12, week 24, and week 36; and post injection at weeks 48, 60, 72, 84, 96, 108, and 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Total Testosterone Maximum Concentration in Part B</measure>
    <time_frame>Post injection at week 1; post injection at week 8; days 0, 4, 7, 11, 14, 21, 28, 42, 56, 70, and 84 post injection at week 20; and post injection at weeks 32, 44, 56, 68, and 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 3rd Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
    <description>Success is defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax &gt;2500 ng/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serum Total Testosterone Level &lt;300 ng/dL at Any Time During the 3rd Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Total Testosterone Average Concentration ≥300 ng/dL During the 3rd Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Serum Total Testosterone Concentration &lt;300 ng/dL Following the 3rd Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Success During the 3rd Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
    <description>Clinical success is defined as having both Cavg and Ctrough between 300 and 1000 ng/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Total Testosterone Maximum Concentration ≤1500, &gt;1500 to &lt;1800, 1800 to 2500, and &gt;2500 ng/dL During the 3rd Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 4th Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
    <description>Success is defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax &gt;2500 ng/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serum Total Testosterone Level &lt;300 ng/dL at Any Time During the 4th Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Average Serum Total Testosterone Concentration ≥300 ng/dL During the 4th Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Serum Total Testosterone Concentration &lt;300 ng/dL Following the 4th Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Success During the 4th Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
    <description>Clinical success is defined as having both Cavg and Ctrough between 300 and 1000 ng/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Total Testosterone Maximum Concentration ≤1500, &gt;1500 to &lt;1800, 1800 to 2500, and &gt;2500 ng/dL During the 4th Injection Interval in Part C</measure>
    <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Collapsed Category for Each Parameter of the Male Patient Global Assessment (M-PGA) at Day 21 of the 3rd Injection Interval in Part C</measure>
    <time_frame>Day 21 post injection at week 14</time_frame>
    <description>M-PGA is a 5-item self-report questionnaire to assess perception of change from pretreatment or baseline in hypogonadal symptoms including confidence/self-esteem, sexual performance, moods/behavior, overall feeling of well-being, and satisfaction with study treatment rated on a 7-point scale where items 1-4 were rated as 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7 (very much worse) and item 5 was rated as 1 (very much satisfied), 2 (much satisfied), 3 (minimally satisfied), 4 (neither satisfied nor dissatisfied), 5 (minimally dissatisfied), 6 (much dissatisfied), 7 (very much dissatisfied). Collapsed ratings: Improved=Very much, much, or minimally improved; Worsened=Very much, much, or minimally worse; No change; Satisfied=Very much, much, or minimally satisfied; Not satisfied=Very much, much, or minimally dissatisfied; No opinion (neither satisfied nor dissatisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index From Baseline to Week 24 in Part C</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Difference in Body Mass Index (BMI) from baseline to week 24 calculated from weight (kg) divided by height squared (m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight From Baseline to Week 24 in Part C</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serum Total Testosterone Concentration &gt;1000, &gt;1100, &gt;1250, and &lt;300 or &gt;1000 ng/dL During the 2nd Injection Interval in Part C2</measure>
    <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Dihydrotestosterone Concentrations During the 2nd Injection Interval in Part C2</measure>
    <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Total Testosterone Concentrations in Part C2</measure>
    <time_frame>Screening; day 0; days 0, 4, 7, 11, and 14 post injection at week 4; weeks 14, 24, 34, and 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Total Testosterone Concentrations Outside the Normal Range in Part C2</measure>
    <time_frame>Screening; day 0; days 0, 4, 7, 11, and 14 post injection at week 4; weeks 14, 24, 34, and 44</time_frame>
    <description>Serum total testosterone concentrations outside the normal range are categorized as &lt;300 ng/dL (below lower limit of normal range) and &gt;1000 ng/dL (above upper limit of normal range)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Assessments of Serum Total Testosterone Concentrations in Part C2</measure>
    <time_frame>Screening; day 0; and weeks 4, 14, 24, 34, and 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Total Testosterone Maximum Concentration in Part C2</measure>
    <time_frame>Screening; day 0; days 0, 4, 7, 11, and 14 post injection at week 4; and weeks 14, 24, 34, and 44</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">531</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Primary Hypogonadism</condition>
  <condition>Secondary Hypogonadism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750 mg dose of testosterone undecanoate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg dose testosterone undecanoate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Undecanoate 750 mg</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Undecanoate 1000 mg</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male with primary or secondary hypogonadism at least 18 years of age and for study
             part C2 weighs ≥143.3 lb (≥65 kg)

          -  Morning screening serum testosterone concentration &lt;300 ng/dL

        Exclusion Criteria:

          -  American Urological Association (AUA) Symptom Score ≥15 or significant prostatic
             symptoms

          -  History of carcinoma, tumors or induration of the prostate or the male mammary gland
             including suspicion thereof

          -  Screening serum prostate-specific antigen (PSA) level &gt;4 ng/mL or hyperplasia of the
             prostate (size &gt;75 cm3 as measured by transrectal ultrasonography)

          -  Past or present liver tumors or acute or chronic hepatic disease with impairment of
             liver function; liver function tests (alanine aminotransferase [ALT], aspartate
             aminotransferase [AST]) exceeding 1.5 times upper limit of normal

          -  History of deep vein thrombosis in the past 5 years or any history of cerebrovascular
             accident

          -  Severe acne

          -  Hypertension (systolic blood pressure &gt;160 mm Hg and diastolic blood pressure &gt;95 mm
             Hg) or coronary heart disease not stabilized by therapy as assessed by the
             investigator

          -  Insulin-dependent diabetes mellitus or uncontrolled non-insulin-dependent diabetes
             mellitus; patients with diabetes are excluded if screening glycated hemoglobin (HbA1C)
             level is &gt;9%

          -  Use of any sex hormones within 28 days (for injectable testosterone preparations) or 7
             days (for oral, gel, patch, etc, testosterone preparations) prior to screening visit
             and throughout the study (exclusive of administered study drug)

          -  Use of steroidal anabolic drugs or supplements (eg, dehydroepiandrosterone [DHEA]) by
             any application method within the 28 days prior to first administration of study drug
             and throughout the study (exclusive of administrated study drug)

          -  Medication with substances which might interfere with testosterone metabolism within
             28 days before the first administration of study drug

          -  History of sleep apnea Insulin-dependent diabetes mellitus

          -  Use of steroidal anabolic drugs or supplements by any application method within the
             28-days prior to the first administration of the study drug and throughout the study
             (exclusive of the administered study drug)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Indevus Pharmaceuticals, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indevus Pharmaceuticals, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2007</study_first_submitted>
  <study_first_submitted_qc>April 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2007</study_first_posted>
  <results_first_submitted>November 7, 2016</results_first_submitted>
  <results_first_submitted_qc>January 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2017</results_first_posted>
  <disposition_first_submitted>August 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 6, 2012</disposition_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>investigational</keyword>
  <keyword>testosterone</keyword>
  <keyword>testosterone undecanoate</keyword>
  <keyword>TU</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>primary hypogonadism</keyword>
  <keyword>secondary hypogonadism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 531 subjects who were enrolled, 524 subjects received study treatment (at least 1 injection). The 7 enrolled subjects who did not receive treatment (2 in Part A and 5 in Part C) were excluded from all analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A-TU 750 mg</title>
          <description>750 mg testosterone undecanoate (TU) in 3 mL oily solution, intramuscularly (IM) every 12 weeks for up to 3 years in Part A</description>
        </group>
        <group group_id="P2">
          <title>A-TU 1000 mg</title>
          <description>1000 mg TU in 4 mL oily solution, IM every 12 weeks for up to 3 years in Part A</description>
        </group>
        <group group_id="P3">
          <title>B-TU 750 mg</title>
          <description>1000 mg TU in 4 mL oily solution, IM at baseline, and then 750 mg TU in 3 mL oily solution at week 8 and again every 10 weeks for up to 23 months in Part B</description>
        </group>
        <group group_id="P4">
          <title>B-TU 1000 mg</title>
          <description>1000 mg TU in 4 mL oily solution, IM at baseline, week 8, and then every 12 weeks for up to 24 months in Part B</description>
        </group>
        <group group_id="P5">
          <title>C-TU 750 mg</title>
          <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
        </group>
        <group group_id="P6">
          <title>C2-TU 750 mg</title>
          <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="112"/>
                <participants group_id="P5" count="130"/>
                <participants group_id="P6" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="93"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="37"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other/Unknown</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all participants who were enrolled and received at least 1 injection</population>
      <group_list>
        <group group_id="B1">
          <title>A-TU 750 mg</title>
          <description>750 mg TU in 3 mL oily solution, IM every 12 weeks for up to 3 years in Part A</description>
        </group>
        <group group_id="B2">
          <title>A-TU 1000 mg</title>
          <description>1000 mg TU in 4 mL oily solution, IM every 12 weeks for up to 3 years in Part A</description>
        </group>
        <group group_id="B3">
          <title>B-TU 750 mg</title>
          <description>1000 mg TU in 4 mL oily solution, IM at baseline, and then 750 mg TU in 3 mL oily solution at week 8 and again every 10 weeks for up to 23 months in Part B</description>
        </group>
        <group group_id="B4">
          <title>B-TU 1000 mg</title>
          <description>1000 mg TU in 4 mL oily solution, IM at baseline, week 8, and then every 12 weeks for up to 24 months in Part B</description>
        </group>
        <group group_id="B5">
          <title>C-TU 750 mg</title>
          <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
        </group>
        <group group_id="B6">
          <title>C2-TU 750 mg</title>
          <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="112"/>
            <count group_id="B5" value="130"/>
            <count group_id="B6" value="23"/>
            <count group_id="B7" value="524"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="10.64"/>
                    <measurement group_id="B2" value="55.9" spread="10.77"/>
                    <measurement group_id="B3" value="55.3" spread="10.40"/>
                    <measurement group_id="B4" value="52.9" spread="10.96"/>
                    <measurement group_id="B5" value="54.2" spread="10.25"/>
                    <measurement group_id="B6" value="54.5" spread="10.63"/>
                    <measurement group_id="B7" value="54.4" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="130"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="97"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part C</title>
        <description>Responders were participants with serum total testosterone average concentration (Cavg) between 300 and 1000 ng/dL derived from the 3rd injection intensive pharmacokinetic (IPK) interval.</description>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
        <population>Pharmacokinetic (PK) population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part C</title>
          <description>Responders were participants with serum total testosterone average concentration (Cavg) between 300 and 1000 ng/dL derived from the 3rd injection intensive pharmacokinetic (IPK) interval.</description>
          <population>Pharmacokinetic (PK) population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" lower_limit="89.7" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Total Testosterone Average Concentration During the 3rd Injection Interval in Part C</title>
        <description>Serum total testosterone Cavg derived from the 3rd injection IPK interval</description>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Average Concentration During the 3rd Injection Interval in Part C</title>
          <description>Serum total testosterone Cavg derived from the 3rd injection IPK interval</description>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494.9373" spread="141.46351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Total Testosterone Maximum Concentration During the 3rd Injection Interval in Part C</title>
        <description>Serum total testosterone maximum concentration (Cmax) derived from the 3rd injection IPK interval</description>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Maximum Concentration During the 3rd Injection Interval in Part C</title>
          <description>Serum total testosterone maximum concentration (Cmax) derived from the 3rd injection IPK interval</description>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="890.583" spread="345.1148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 3rd Injection in Part C</title>
        <description>Serum total testosterone concentration at the end of the dosing interval (Ctrough) derived from the 3rd injection IPK interval</description>
        <time_frame>Day 70 post injection at week 14</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 3rd Injection in Part C</title>
          <description>Serum total testosterone concentration at the end of the dosing interval (Ctrough) derived from the 3rd injection IPK interval</description>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323.522" spread="99.1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 4th Injection Interval in Part C</title>
        <description>Responders were participants with serum total testosterone Cavg between 300 and 1000 ng/dL derived from the 4th injection IPK interval.</description>
        <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 4th Injection Interval in Part C</title>
          <description>Responders were participants with serum total testosterone Cavg between 300 and 1000 ng/dL derived from the 4th injection IPK interval.</description>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="92.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Total Testosterone Average Concentration During the 4th Injection Interval in Part C</title>
        <description>Serum total testosterone Cavg derived from the 4th injection IPK interval</description>
        <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Average Concentration During the 4th Injection Interval in Part C</title>
          <description>Serum total testosterone Cavg derived from the 4th injection IPK interval</description>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="514.2792" spread="163.11476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Total Testosterone Maximum Concentration During the 4th Injection Interval in Part C</title>
        <description>Serum total testosterone Cmax derived from the 4th injection IPK interval</description>
        <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Maximum Concentration During the 4th Injection Interval in Part C</title>
          <description>Serum total testosterone Cmax derived from the 4th injection IPK interval</description>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="837.648" spread="412.0692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 4th Injection in Part C</title>
        <description>Serum total testosterone Ctrough derived from the 4th injection IPK interval</description>
        <time_frame>Day 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 4th Injection in Part C</title>
          <description>Serum total testosterone Ctrough derived from the 4th injection IPK interval</description>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342.800" spread="106.9180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 2nd Injection Interval in Part C2</title>
        <description>Success was defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax &gt;2500 ng/dL.</description>
        <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 2nd Injection Interval in Part C2</title>
          <description>Success was defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax &gt;2500 ng/dL.</description>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax ≤1500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax 1800-2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Total Testosterone Average Concentration During the 2nd Injection Interval in Part C2</title>
        <description>Serum total testosterone Cavg derived from the 2nd injection IPK interval</description>
        <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Average Concentration During the 2nd Injection Interval in Part C2</title>
          <description>Serum total testosterone Cavg derived from the 2nd injection IPK interval</description>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449.6455" spread="157.00582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Total Testosterone Maximum Concentration During the 2nd Injection Interval in Part C2</title>
        <description>Serum total testosterone Cmax derived from the 2nd injection IPK interval</description>
        <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Maximum Concentration During the 2nd Injection Interval in Part C2</title>
          <description>Serum total testosterone Cmax derived from the 2nd injection IPK interval</description>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="689.002" spread="266.9442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Total Testosterone at the End of the Dosing Interval Following the 2nd Injection in Part C2</title>
        <description>Serum total testosterone Ctrough derived from the 2nd injection IPK interval</description>
        <time_frame>Day 70 post injection at week 4</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone at the End of the Dosing Interval Following the 2nd Injection in Part C2</title>
          <description>Serum total testosterone Ctrough derived from the 2nd injection IPK interval</description>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.419" spread="105.3124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Total Testosterone Maximum Concentration in Part A</title>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, 70, and 84 post injection at week 1, week 12, week 24, and week 36; and post injection at weeks 48, 60, 72, 84, 96, 108, and 120</time_frame>
        <population>Total patient sample includes participants who were enrolled and received at least 1 injection; participants without any IPK sample collections were excluded from this analysis (20 from A-TU 750 mg and 11 from A-TU 1000 mg)</population>
        <group_list>
          <group group_id="O1">
            <title>A-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM every 12 weeks for up to 3 years in Part A</description>
          </group>
          <group group_id="O2">
            <title>A-TU 1000 mg</title>
            <description>1000 mg TU in 4 mL oily solution, IM every 12 weeks for up to 3 years in Part A</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Maximum Concentration in Part A</title>
          <population>Total patient sample includes participants who were enrolled and received at least 1 injection; participants without any IPK sample collections were excluded from this analysis (20 from A-TU 750 mg and 11 from A-TU 1000 mg)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="805.867" spread="308.5417"/>
                    <measurement group_id="O2" value="1023.591" spread="394.3051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Total Testosterone Maximum Concentration in Part B</title>
        <time_frame>Post injection at week 1; post injection at week 8; days 0, 4, 7, 11, 14, 21, 28, 42, 56, 70, and 84 post injection at week 20; and post injection at weeks 32, 44, 56, 68, and 80</time_frame>
        <population>Total patient sample includes participants who were enrolled and received at least 1 injection; participants without any IPK sample collections were excluded from this analysis (2 from B-TU 750 mg and 12 from B-TU 1000 mg)</population>
        <group_list>
          <group group_id="O1">
            <title>B-TU 750 mg</title>
            <description>1000 mg TU in 4 mL oily solution, IM at baseline, and then 750 mg TU in 3 mL oily solution at week 8 and again every 10 weeks for up to 23 months in Part B</description>
          </group>
          <group group_id="O2">
            <title>B-TU 1000 mg</title>
            <description>1000 mg TU in 4 mL oily solution, IM at baseline, week 8, and then every 12 weeks for up to 24 months in Part B</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Maximum Concentration in Part B</title>
          <population>Total patient sample includes participants who were enrolled and received at least 1 injection; participants without any IPK sample collections were excluded from this analysis (2 from B-TU 750 mg and 12 from B-TU 1000 mg)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="986.364" spread="330.4247"/>
                    <measurement group_id="O2" value="1047.739" spread="571.1648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 3rd Injection Interval in Part C</title>
        <description>Success is defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax &gt;2500 ng/dL.</description>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 3rd Injection Interval in Part C</title>
          <description>Success is defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax &gt;2500 ng/dL.</description>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax ≤1500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="87.5" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax 1800-2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 1 Serum Total Testosterone Level &lt;300 ng/dL at Any Time During the 3rd Injection Interval in Part C</title>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serum Total Testosterone Level &lt;300 ng/dL at Any Time During the 3rd Injection Interval in Part C</title>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" lower_limit="42.2" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Total Testosterone Average Concentration ≥300 ng/dL During the 3rd Injection Interval in Part C</title>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Total Testosterone Average Concentration ≥300 ng/dL During the 3rd Injection Interval in Part C</title>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="90.9" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Serum Total Testosterone Concentration &lt;300 ng/dL Following the 3rd Injection Interval in Part C</title>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis); an additional 57 participants who did not have serum total testosterone concentrations &lt;300 ng/dL were also excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Serum Total Testosterone Concentration &lt;300 ng/dL Following the 3rd Injection Interval in Part C</title>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis); an additional 57 participants who did not have serum total testosterone concentrations &lt;300 ng/dL were also excluded from analysis</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="17.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Success During the 3rd Injection Interval in Part C</title>
        <description>Clinical success is defined as having both Cavg and Ctrough between 300 and 1000 ng/dL</description>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Success During the 3rd Injection Interval in Part C</title>
          <description>Clinical success is defined as having both Cavg and Ctrough between 300 and 1000 ng/dL</description>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" lower_limit="44.8" upper_limit="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Total Testosterone Maximum Concentration ≤1500, &gt;1500 to &lt;1800, 1800 to 2500, and &gt;2500 ng/dL During the 3rd Injection Interval in Part C</title>
        <time_frame>Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Total Testosterone Maximum Concentration ≤1500, &gt;1500 to &lt;1800, 1800 to 2500, and &gt;2500 ng/dL During the 3rd Injection Interval in Part C</title>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax ≤1500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="87.5" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;1500-&lt;1800 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="2.9" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax 1800-2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 4th Injection Interval in Part C</title>
        <description>Success is defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax &gt;2500 ng/dL.</description>
        <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 4th Injection Interval in Part C</title>
          <description>Success is defined as having ≥85% of participants with Cmax ≤1500 ng/dL, ≤5% of participants with Cmax 1800-2500 ng/dL, and no participants with Cmax &gt;2500 ng/dL.</description>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax ≤1500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="87.2" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax 1800-2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.2" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 1 Serum Total Testosterone Level &lt;300 ng/dL at Any Time During the 4th Injection Interval in Part C</title>
        <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serum Total Testosterone Level &lt;300 ng/dL at Any Time During the 4th Injection Interval in Part C</title>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="28.2" upper_limit="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Average Serum Total Testosterone Concentration ≥300 ng/dL During the 4th Injection Interval in Part C</title>
        <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Average Serum Total Testosterone Concentration ≥300 ng/dL During the 4th Injection Interval in Part C</title>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="92.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Serum Total Testosterone Concentration &lt;300 ng/dL Following the 4th Injection Interval in Part C</title>
        <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis); an additional 57 participants who did not have serum total testosterone concentrations &lt;300 ng/dL were also excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Serum Total Testosterone Concentration &lt;300 ng/dL Following the 4th Injection Interval in Part C</title>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis); an additional 57 participants who did not have serum total testosterone concentrations &lt;300 ng/dL were also excluded from analysis</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Success During the 4th Injection Interval in Part C</title>
        <description>Clinical success is defined as having both Cavg and Ctrough between 300 and 1000 ng/dL</description>
        <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Success During the 4th Injection Interval in Part C</title>
          <description>Clinical success is defined as having both Cavg and Ctrough between 300 and 1000 ng/dL</description>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="53.2" upper_limit="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Total Testosterone Maximum Concentration ≤1500, &gt;1500 to &lt;1800, 1800 to 2500, and &gt;2500 ng/dL During the 4th Injection Interval in Part C</title>
        <time_frame>Days 0, 4, 7, 11, 42, and 70 post injection at week 24</time_frame>
        <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Total Testosterone Maximum Concentration ≤1500, &gt;1500 to &lt;1800, 1800 to 2500, and &gt;2500 ng/dL During the 4th Injection Interval in Part C</title>
          <population>Steady-state PK population includes all participants in the PK population with non-missing 4th and 5th injection serum total testosterone concentrations (26 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax ≤1500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="87.2" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;1500 to &lt;1800 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.2" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax 1800 to 2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.2" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants by Collapsed Category for Each Parameter of the Male Patient Global Assessment (M-PGA) at Day 21 of the 3rd Injection Interval in Part C</title>
        <description>M-PGA is a 5-item self-report questionnaire to assess perception of change from pretreatment or baseline in hypogonadal symptoms including confidence/self-esteem, sexual performance, moods/behavior, overall feeling of well-being, and satisfaction with study treatment rated on a 7-point scale where items 1-4 were rated as 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7 (very much worse) and item 5 was rated as 1 (very much satisfied), 2 (much satisfied), 3 (minimally satisfied), 4 (neither satisfied nor dissatisfied), 5 (minimally dissatisfied), 6 (much dissatisfied), 7 (very much dissatisfied). Collapsed ratings: Improved=Very much, much, or minimally improved; Worsened=Very much, much, or minimally worse; No change; Satisfied=Very much, much, or minimally satisfied; Not satisfied=Very much, much, or minimally dissatisfied; No opinion (neither satisfied nor dissatisfied).</description>
        <time_frame>Day 21 post injection at week 14</time_frame>
        <population>Pharmacokinetic (PK) population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants by Collapsed Category for Each Parameter of the Male Patient Global Assessment (M-PGA) at Day 21 of the 3rd Injection Interval in Part C</title>
          <description>M-PGA is a 5-item self-report questionnaire to assess perception of change from pretreatment or baseline in hypogonadal symptoms including confidence/self-esteem, sexual performance, moods/behavior, overall feeling of well-being, and satisfaction with study treatment rated on a 7-point scale where items 1-4 were rated as 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7 (very much worse) and item 5 was rated as 1 (very much satisfied), 2 (much satisfied), 3 (minimally satisfied), 4 (neither satisfied nor dissatisfied), 5 (minimally dissatisfied), 6 (much dissatisfied), 7 (very much dissatisfied). Collapsed ratings: Improved=Very much, much, or minimally improved; Worsened=Very much, much, or minimally worse; No change; Satisfied=Very much, much, or minimally satisfied; Not satisfied=Very much, much, or minimally dissatisfied; No opinion (neither satisfied nor dissatisfied).</description>
          <population>Pharmacokinetic (PK) population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confidence or Self-Esteem Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="75.0" upper_limit="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confidence or Self-Esteem No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="0.8" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confidence or Self-Esteem Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with Sexual Performance Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="71.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with Sexual Performance No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="0.8" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with Sexual Performance Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.0" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Moods and Behavoir Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" lower_limit="72.9" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Moods and Behavoir No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="2.7" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Moods and Behavoir Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overal Feeling of Well-Being Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" lower_limit="73.9" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overal Feeling of Well-Being No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="1.7" upper_limit="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overal Feeling of Well-Being Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with Study Treatment Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" lower_limit="87.1" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with Study Treatment No Opinion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="0.0" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with Study Treatment Not Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index From Baseline to Week 24 in Part C</title>
        <description>Difference in Body Mass Index (BMI) from baseline to week 24 calculated from weight (kg) divided by height squared (m2)</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis); 1 additional participant did not have a measurement at week 24 and was also excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index From Baseline to Week 24 in Part C</title>
          <description>Difference in Body Mass Index (BMI) from baseline to week 24 calculated from weight (kg) divided by height squared (m2)</description>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis); 1 additional participant did not have a measurement at week 24 and was also excluded from analysis</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.9543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight From Baseline to Week 24 in Part C</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis); 1 additional participant did not have a measurement at week 24 and was also excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>C-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 20 months in Part C</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight From Baseline to Week 24 in Part C</title>
          <population>PK population includes participants who had a minimum of 4 serum total testosterone concentration values within the 3rd injection interval (13 participants were excluded from analysis); 1 additional participant did not have a measurement at week 24 and was also excluded from analysis</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="3.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 1 Serum Total Testosterone Concentration &gt;1000, &gt;1100, &gt;1250, and &lt;300 or &gt;1000 ng/dL During the 2nd Injection Interval in Part C2</title>
        <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serum Total Testosterone Concentration &gt;1000, &gt;1100, &gt;1250, and &lt;300 or &gt;1000 ng/dL During the 2nd Injection Interval in Part C2</title>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;1100 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;1250 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &lt;300 or &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Dihydrotestosterone Concentrations During the 2nd Injection Interval in Part C2</title>
        <time_frame>Days 0, 4, 7, 11, 14, and 70 post injection at week 4</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Dihydrotestosterone Concentrations During the 2nd Injection Interval in Part C2</title>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.33" spread="111.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.85" spread="188.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.74" spread="197.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332.92" spread="210.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324.74" spread="191.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 70 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.71" spread="113.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Total Testosterone Concentrations in Part C2</title>
        <time_frame>Screening; day 0; days 0, 4, 7, 11, and 14 post injection at week 4; weeks 14, 24, 34, and 44</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Concentrations in Part C2</title>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.629" spread="75.8138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.363" spread="81.6797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 at Week 4 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.669" spread="112.7259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 post injection at Week 4 (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="578.419" spread="304.6675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 post injection at Week 4 (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606.484" spread="266.4847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 post injection at Week 4 (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="580.614" spread="244.3727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 post injection at week 4 (n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="545.236" spread="234.5882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.419" spread="105.3124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.215" spread="126.1430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34 (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374.698" spread="161.7627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375.797" spread="136.5283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Total Testosterone Concentrations Outside the Normal Range in Part C2</title>
        <description>Serum total testosterone concentrations outside the normal range are categorized as &lt;300 ng/dL (below lower limit of normal range) and &gt;1000 ng/dL (above upper limit of normal range)</description>
        <time_frame>Screening; day 0; days 0, 4, 7, 11, and 14 post injection at week 4; weeks 14, 24, 34, and 44</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Total Testosterone Concentrations Outside the Normal Range in Part C2</title>
          <description>Serum total testosterone concentrations outside the normal range are categorized as &lt;300 ng/dL (below lower limit of normal range) and &gt;1000 ng/dL (above upper limit of normal range)</description>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 at Week 4, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 at Week 4, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 post injection at Week 4, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 post injection at Week 4, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 post injection at Week 4, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 post injection at Week 4, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 post injection at Week 4, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 post injection at Week 4, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 post injection at Week 4, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 post injection at Week 4, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44, &lt;300 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44, &gt;1000 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Assessments of Serum Total Testosterone Concentrations in Part C2</title>
        <time_frame>Screening; day 0; and weeks 4, 14, 24, 34, and 44</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Assessments of Serum Total Testosterone Concentrations in Part C2</title>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.629" spread="75.8138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.363" spread="81.6797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.669" spread="112.7529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.419" spread="105.3124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.215" spread="126.1430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34 (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374.698" spread="161.7627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375.797" spread="136.5283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Total Testosterone Maximum Concentration in Part C2</title>
        <time_frame>Screening; day 0; days 0, 4, 7, 11, and 14 post injection at week 4; and weeks 14, 24, 34, and 44</time_frame>
        <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>C2-TU 750 mg</title>
            <description>750 mg TU in 3 mL oily solution, IM at baseline, week 4, and then every 10 weeks for up to 12 months in Part C2</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Maximum Concentration in Part C2</title>
          <population>Total patient sample/PK sample includes participants who were enrolled, received injection 2, and had at least 1 post-injection 2 IPK sample (no participants were excluded)</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="711.343" spread="257.5643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study (up to 3 years)</time_frame>
      <desc>Includes all participants who were enrolled and received at least 1 injection, pooled into groups of maximum TU dose received at any time during the study</desc>
      <group_list>
        <group group_id="E1">
          <title>TU 750 mg</title>
          <description>750 mg TU in 3 mL oily solution, IM at baseline and during the study in Part A, C, or C2 (includes participants from A-750 mg, C-750 mg, and C2-750 mg)</description>
        </group>
        <group group_id="E2">
          <title>TU 1000 mg</title>
          <description>1000 mg TU in 4 mL oily solution, IM at any time during the study in Part A or B (includes participants from A-1000 mg, B-750 mg, and B-1000 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Arrhythmia superventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdonimal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Spinal ostheoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoae</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Musculoskelatal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Coordinator</name_or_title>
      <organization>Endo Pharmaceuticals Inc.</organization>
      <email>clinicalsite.inquiries@endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

